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Abstract 
Purpose: Adjuvant FOLFOX (5‑fluorouracil and oxaliplatin) chemotherapy benefits stage III colon cancer patients. 
However, it still results in side effects and increased cost. Reducing cycles had been thought to decrease these prob‑
lems. This retrospective study aimed to find the appropriate number of treatment cycles that are sufficient for treating 
these patients.
Patients and methods: A total of 213 stage III colon cancer patients receiving adjuvant FOLFOX therapy were 
retrospectively recruited. Demographic data were collected for analysis. Survival analyses were performed between 
all cases of patients receiving above and below a certain cycle number. If a significant difference was reached at that 
cycle number, multivariate Cox Regression was performed with those factors resulting in p < 0.2 to assess the inde‑
pendent prognostic factors.
Results: The 5‑year overall survival rate of patients was 77.9 %, and the 3‑year disease‑free survival was 76.7 %. For 
overall survival, a significant benefit was noted for treatment of at least 8 cycles, for disease‑free survival, significant 
differences were apparent from patient data of those who underwent from 7 to 12 treatment cycles. Multivariate 
survival analysis of that patient data at cycle 8 for overall survival and cycle 7 for disease free survival revealed cycle 
number as the only independent prognostic factor (p = 0.04, 0.048).
Conclusion: Cycle number of adjuvant FOLFOX is a significant prognostic factor for stage III colon cancer patients. At 
least 8 cycles are needed to have an overall survival benefit, and 7 to disease‑free survival.
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Background
For patients with colon cancer, surgical resection offers 
the only potential cure. Post-operative adjuvant chemo-
therapy has been demonstrated to improve outcomes 
in high-risk patients since the 1990s, and it has become 
standard treatment (O’Connell et al. 1997; Moertel et al. 
1990; Wolmark et  al. 1993). The results of the Multi-
center International Study of oxaliplatin/5-fluorouracil/
leucovorin in the adjuvant treatment of colon cancer 
(MOSAIC) trial in 2004 (Andre et  al. 2004), along with 
the National Surgical Adjuvant Breast and Bowel Pro-
ject (NSABP) C-07 report in 2007 (Kuebler et al. 2007), 
revealed that adding oxaliplatin to a regimen of fluoro-
uracil (FU) combined with leucovorin (LV) produced 
a significant improvement in 3-year disease-free sur-
vival (DFS). FOLFOX increased overall survival in the 
MOSAIC trial (Andre et  al. 2009). After these findings, 
12 cycles of FOLFOX [folinic acid (leucovorin), fluoro-
uracil, and oxaliplatin] became the standard adjuvant 
regimen for stage III colon cancer treatment.
Despite the efficacy of FOLFOX treatment for stage 
III colon cancer, this treatment leads to significant cost 
increase, toxicity, and inconvenience. In particular, oxali-
platin-induced cumulative dose-dependent neurotoxicity 
is a clinically relevant issue. Peripheral neuropathy was 
reported for 92.1 % of patients receiving treatments, and 
the incidence of grade 3 neurotoxicity 1 year after com-
pletion was estimated to be 12  % in the MOSAIC trial. 
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Approximately 50 % of patients suffered from grade 1 or 
2 neurotoxicity in the second post-treatment year (Andre 
et al. 2004, 2009).
Previous studies showed that oxaliplatin-induced 
neurotoxicity presented at the cumulative dose of 
785–850 mg/m2, (de Gramont et al. 2000; Grothey et al. 
2000; Grothey 2005) which corresponds to the 8–10th 
cycle of FOLFOX. We wanted to examine if FOLFOX 
cycles could be reduced in order to lessen the associ-
ated neurotoxicity, while preserving the survival effects 
of treatment. No trial has compared different numbers 
of FOLFOX cycles yet. However, there were some find-
ings regarding oxaliplatin dosage in the MOSAIC and 
NSABP C-07 studies (Andre et  al. 2009; Kuebler et  al. 
2007). In the MOSAIC trial, the median oxaliplatin dose 
received per patient in the FOLFOX4 group was 810 mg/
m2, 79.4 % of the 12-cycle protocol dose (1020 mg/m2). 
In the FLOX group of the NSABP C-07 trial, the median 
oxaliplatin dose was 677  mg/m2, 88.5  % of the 9-cycle 
protocol dose (765  mg/m2). The median dose of the 
NSAPBP C-07 FLOX group was 66.4  % of the 12-cycle 
dosage.
If a reduced number of FOLFOX cycles can have the 
same survival benefit and decreased side effects, it would 
be beneficial to both patients and care providers. It is our 
aim, through a retrospective review, to evaluate the num-
ber of adjuvant FOLFOX cycles that are necessary to 
achieve survival benefits for stage III colon cancer patients.
Results
A total of 692 consecutive cases of stage III colorectal 
cancer were collected in the section of colorectal surgery 
database at Taipei Veterans General Hospital. Among 
them, 210 cases were excluded due to inadequate data 
or lack of follow-up, 49 were excluded for not receiving 
any chemotherapy, and 220 were excluded for receiv-
ing chemotherapy other than FOLFOX. As a result, 213 
cases of patients with stage III colon adenocarcinoma 
treated with adjuvant mFOLFOX6 were analyzed. Table 1 
shows demographic data. Among the study population of 
median age 61.7 years-old, there was a predominant dis-
tribution of males (54.5 %), low preoperative CEA (<5 ng/
mL; 61.5 %), pT1–3 (90.6 %), pN1 (60.1 %), and left side 
colon localization (59.6  %). There were also high rates 
of well- or moderately-differentiated tumors (88.3  %), 
patients receiving adjuvant chemotherapy within 8 weeks 
of the operation (95.3  %), patients who had more than 
12 lymph nodes harvested (91.1 %), and patients with an 
ECOG performance status grade of 0 (90.6 %).
The median follow-up period was 54.0  months. The 
recurrence rate was 26.3  %. The 5-year OS was 77.9  %, 
and the 3-year DFS was 76.7 %.
Table  2 shows the cumulative percentage of patients 
fulfilling each cycle number of chemotherapy. One hun-
dred and eighteen patients (55.4  %) completed the full 
12 cycles. Of the 95 patients (44.6 %) not completing full 
cycles (CFC), 81 patients (85.3  %) received 5-FU based 
chemotherapy as replacement chemotherapy, via either 
oral or intravenous administration.
Table 1 Demographic data of patients
Sex
 Men 114 54.50 %
 Woman 99 45.50 %
Age (years)
 Median (range) 61.65 29–88
 <70 152 71.40 %
 ≥70 61 28.60 %
Performance status
 0 193 90.60 %
 1 17 8.00 %
 2 3 1.40 %
Median OPD follow‑up (months) 54.03
5 year survival rate 77.90 %
5 year cancer specific survival 82.20 %
3 year disease free survival 76.70 %
Recurrence rate 26.30 %
Pathological staging
 pT classification
  pT1–3 193 90.60 %
  pT4 20 9.40 %
 pN classificaton
  pN1 128 60.10 %
  pN2 85 39.90 %
Tumor localization
 Right 85 40.40 %
 Left 128 59.60 %
Obstruction/Perforation 35 16.40 %
Histopathology grade
 Well, and moderate differentiated 188 88.30 %
 Poor differentiated 22 10.30 %
 Missing 3 1.40 %
Pre‑operative CEA level
 CEA >5 70 32.9 %
 CEA ≤5 131 61.5 %
 Missing 12 5.6 %
Time to chemotherapy (weeks)
 ≥8 10 4.70 %
 <8 203 95.30 %
Lymph nodes harvested
 Lymph nodes <12 19 8.90 %
 Lymph nodes ≥12 194 91.10 %
Page 3 of 7Tsai et al. SpringerPlus  (2016) 5:1318 
For overall survival (OS) of colorectal cancer patients 
(Fig. 1), the trend is apparent. A significant difference was 
noted when comparing groups of patients that received 
at least 8 cycles and those that received less than 8 cycles. 
When differentiating between groups using conditions of 
more than 8 cycles, the p value decreased dramatically 
and fluctuated around 0.05, with use of 9 cycles result-
ing in p = 0.07 and use of 12 cycles resulting in p = 0.06. 
Multivariate survival analysis of patients stratified 
according to 8 cycles of treatment (Table 3), also includ-
ing pT, ECOG, lymph node number, and perforation/
obstruction, revealed treatment cycle number as the only 
independent prognostic factor (p = 0.04).
For disease free survival (DFS) (Fig. 2), significant dif-
ference was noted when comparing groups of patients 
that received at least 7 cycles and those that received less 
than 7 cycles, significance was maintained for increasing 
numbers of cycles up to 12. Multivariate survival analy-
sis of patients stratified according to 7 cycles of treatment 
(Table 4), also including time to chemotherapy, revealed 
cycle number as the only independent prognostic factor 
(p = 0.048).
Discussion
Cycle number does matter. This study reveals that sur-
vival benefits of adjuvant FOLFOX treatment for stage 
III colon cancer patients require at least 7 or 8 cycles. 
Specifically, 8 cycles are required for OS benefits, and 7 
cycles are required for DFS benefits. It is very likely that 
those OS and DFS benefits are also conferred to patients 
who receive up to 12 cycles.
The initial demonstration of efficacy of adjuvant 
5-FU plus levamisole treatment was based on a study of 
12-month treatment of colon cancer patients (Moertel 
et al. 1990). Subsequent studies confirmed that 6-month 
treatment resulted in similar effects (Haller et  al. 2005; 
Andre et  al. 2003, 2007), and 3  months of protracted 
venous 5-FU infusion was shown to be as effective as 
6  months of standard bolus 5-FU/leucovorin and sig-
nificantly less toxic (Chau et  al. 2005). As for FOLFOX, 
our results suggest that treatments should be given in as 
many courses as possible up to the complete course, and 
if that is not possible, at least 7 cycles should be adminis-
tered. However, as stated earlier, the annoying neurotox-
icity side effect of FOLFOX appears at the 8–10th cycle 
administration. This time period is the critical time to 
gain or lose survival benefits. Although treatment series 
of fewer cycles showed some potential to ameliorate this 
neurotoxicity (Hosokawa et  al. 2012; Milla et  al. 2009), 
recent studies failed to show any convincing benefit (Oki 
et al. 2015; Pachman et al. 2015; Zimmerman et al. 2015; 
Loprinzi et  al. 2014), even on a molecular basis (Ruzzo 
et al. 2014). It is still a challenge to be solved. Any “wait 
and go” policy to reduce side effects needs to be evalu-
ated in a larger cohort of patients (Kochi et al. 2011). Our 
results notice the importance of treatments reducing the 
likelihood of adverse effect. This should be verified on 
solid base.
Patient CFC rate for this study was 55.9  %, which is 
lower than the 74.7 % in the MOSAIC trial. However, the 
6-year OS rate (72.6  %) and 3-year DFS (75.6  %) of our 
patients are close to of the data from the MOSAIC study 
(72.9 and 78.2 %, respectively). In the NSABP C-07 trial, 
the 3-year DFS was 76.1  % for FLOX arm (Andre et  al. 
2004; Kuebler et al. 2007). However, the two studies both 
included stage II colon cancer patients in whom benefit of 
adjuvant chemotherapy is small and the survival outcome 
was more favorable. This CFC rate for stage III patients 
Table 2 Patients complete each FOLFOX cycle
FOLFOX cycles (%) Cumulative percentage (%)
Total 213
1 9 4.2 4.2
2 5 2.3 6.6
3 6 2.8 9.4
4 8 3.8 13.1
5 5 2.3 15.5
6 29 13.6 29.1
7 5 2.3 31.5
8 9 4.2 35.7
9 7 3.3 39.0
10 10 4.7 43.7
11 2 0.9 44.6
12 118 55.4 100.0
Fig. 1 p value and hazard ratio with 95 % confidence interval of 
patients stratified to each cycle of treatment for overall survival
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is similar to that of another cohort of American veteran 
stage III colorectal cancer patients (58 %) (Aspinall et al. 
2015). Over 90 % of patients after oxaliplatin disruption 
had maintenance treatments. The maintenance treatment 
cycles were not included in total accumulative cycles. 
This might be the reason of our good outcome.
We did collect the reasons for discontinuing oxali-
platin. Half (50.5  %) were due to intolerance of adverse 
effect. Physicians’ will to avoid adverse effects in advance 
accounts for the other 23.2 %. Disease progression made 
the switching to other regimen explained another 16.8. 
The remaining 9.5 % was patients’ will to terminate with-
out apparent reasons.
This retrospective and small population study had 
many shortcomings. These comparisons at certain 
cutoff cycle numbers are comparisons of heterogene-
ous populations: all patients who received below a cer-
tain number of cycles compared to those that received 
above that number. It is not a head-to-head comparison 
between two different cycle numbers. This was because 
we had a small patient population satisfying the inclu-
sion criteria. Furthermore, cumulative dose intensity 
was not included here. We agree it would strengthen 
our study if it was analyzed. Recently, Kumar et  al. 
(2015) published a report in which they used a similar 
analysis method during a similar period and showed 
that early discontinuation of FOLFOX (cycle of FOL-
FOX, ≥10 vs  <10) was not associated with differences 
in survival outcomes. They also mentioned similar 
findings after titrating cycle number at 9, and 11. Their 
survival benefit persisted under considering the num-
ber of treatment cycles as a continuous variable when 
examined for survival. We do not have a good expla-
nation for this contrary finding. Reviewing the demo-
graphic distribution, we found that the major difference 
in patient data was that they had a population 2 times 
bigger than ours. However, there was no information 
regarding the ratio fulfilling each cycle. A higher ratio 
of our patients received chemotherapy within 8 weeks 
after operations.
Additional, with a CFC rate of 55.4  %, the compari-
son would be more weighted toward patients receiving a 
larger number of FOLFOX cycles. This may be the main 
reason for persistent significant differences up to the last 
cycle. The other major possible contributing factor is that 
85.6 % of those who did not receive CFC received other 
5-FU based replacements that were administered orally or 
Table 3 Multivariate survival analysis of patients stratified according to 8 cycles of treatment for overall survival
Univariate COX regression Multivariats logistic regression
Hazard ratio 95 % Cl p value Hazard ratio 95 % Cl p value
Sex (man vs woman) 1.13 0.62–2.04 0.7
Age (≥70 years vs <70 years) 1.22 0.65–2.23 0.53
T stage (4 vs 1–3) 1.77 0.79–3.97 0.17 1.21 0.51–2.89 0.67
N stage (2 vs 1) 1.31 0.73–2.37 0.37
Histo‑pathological grade (poor differentiated vs. well, 
moderated differentiated)
1.51 0.78 –5.23 0.35
Site (right vs left) 1.1 0.61–1.98 0.76
Pre‑operative CEA (≥ 5 vs. < 5) 0.9 0.46–1.75 0.76
Performance status (1 and 2 vs.0) 2.08 0.93–4.66 0.08 1.91 0.83–4.40 0.13
FOLFOX cycles (≥8 vs <8) 0.54 0.30–0.99 0.043 0.52 0.28–0.97 0.038
Lymph nodes (≥12 vs. <12) 3.1 0.75–12.89 0.12 2.9 0.68–12.31 0.15
Time to treatment (≥8 vs <8 weeks) 1.71 0.61–4.79 0.31
Perforation or obstruction 1.92 0.99–3.73 0.053 1.41 0.68–2.93 0.36
Fig. 2 p value and hazard ratio with 95 % confidence interval of 
patients stratified to each cycle of treatment for disease free survival
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intravenously to finish the scheduled course. This was not 
included in analysis. All of these potential issues are prob-
lems that can be associated with a retrospective study.
Currently, the International Duration Evaluation 
of Adjuvant chemotherapy (IDEA) collaboration is 
undertaking a prospective analysis combining sev-
eral randomized trials of FOLFOX (6 vs. 12 cycles) or 
Capecitabine plus Oxaliplatin(XELOX) (4 vs. 8 cycles) 
for stage III colon cancer treatment (Andre et al. 2013). 
Researchers want to evaluate if half of the standard cycle 
number is non-inferior to a full complement of treatment 
cycles with respect to 3-year DFS. However, our results 
reveal that at least 7 cycles may be needed to obtain the 
DFS benefit.
In conclusion, the number of adjuvant FOLFOX cycles 
administered matters in stage III colon cancer therapy. At 
least 8 cycles are needed to increase OS, and 7 cycles are 
necessary to prolong DFS. The DFS benefits are also pre-
sent for patients received more cycles of chemotherapy 
up to the full course.
Methods
Study setting and population
This is a retrospective observation cohort study of 
patients treated between June 2005 and June 2012. Cases 
were retrieved from the section of colorectal surgery 
database at Taipei Veterans General Hospital. Cases of 
stage III colon adenocarcinoma in which patients under-
went curative resections and adjuvant FOLFOX chemo-
therapy were retrieved. The primary colon tumor site 
was defined as the region from the cecum to the sigmoid 
colon, excluding the rectum and recto-sigmoid junc-
tion. No patients received neoadjuvant chemotherapy or 
radiotherapy.
Patients were followed through June 2015. The stand-
ard follow-up schedule was set at 3-month intervals for 
up to 2  years, 6-month intervals for up to 5  years, and 
then annually. During follow-up visits, all relevant data 
were collected. Patient with lost follow-up was excluded.
The Eastern Cooperative Oncology Group (ECOG) 
method was used to quantify general performance status 
(Sargent et al. 2005).
All patients signed informed consents to be enrolled 
into the database. This study was approved by the Local 
Survey and Behavior Ethics Committee.
Chemotherapy regimens
A modified FOLFOX6 (mFOLFOX6) regimen was 
adopted. Oxaliplatin was administered via 2-h intrave-
nous infusion (IVI) at a dose of 85 mg/m2. Then, Leuco-
vorin was administered via 2-h IVI at a dose of 400 mg/
m2, followed by a 5-FU bolus at a dose of 400 mg/m2 on 
day 1, and then 5-FU was administered via 46 to 48-h 
IVI a dose of 2400 mg/m2 from day 1. The next cycle was 
scheduled for 2 weeks later.
Primary outcome measures
The primary outcomes were overall survival (OS) and dis-
ease-free survival (DFS). OS was defined as the time from 
operation day to death from any cause. DFS was defined as 
the time from operation day to either colon cancer recurrence 
or death, whichever occurred first. Previously, 3-year DFS has 
been used as a surrogate marker for OS in clinical trials of 
adjuvant chemotherapy for colon cancer (Sargent et al. 2005).
Statistical analysis
General clinicopathological data were collected for analy-
ses, including age, sex, preoperative carcinoembryonic 
Table 4 Multivariate survival analysis of patients stratified according to 7 cycles of treatment for disease-free survival
Univariate COX regression Multivariats logistic regression
Hazard ratio 95 %  Cl p value Hazard ratio 95 %  Cl p value
Sex (man vs woman) 0.94 0.55–1.62 0.83
Age (≥70 years vs <70 years) 0.9 0.49–1.65 0.73
T stage (4 vs 1–3) 1.63 0.70–3.81 0.26
N stage (2 vs 1) 1.01 0.59–1.76 0.96
Histo‑pathological grade (poor differentiated vs. well, moderated 
differentiated)
0.73 0.262–2.017 0.539
Site (right vs left) 1.08 0.62–1.86 0.8
Pre‑operative CEA (≥5 vs. <5) 0.79 0.42–1.47 0.45
Performance status (1 and 2 vs.0) 1.07 0.43– 0.68 0.89
FOLFOX cycles (≥7 vs. <7) 0.56 0.32–0.97 0.04 0.57 0.33–0.996 0.048
Lymph nodes (≥12 vs. <12) 0.67 0.300–1.48 0.32
Time to treatment (≥8 vs <8 weeks) 2.22 0.08–6.15 0.12 2.2 0.73–5.64 0.18
Perforation or obstruction 1.52 0.78–2.96 0.21
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antigen (CEA), detailed pT and pN staging, tumor site, 
obstruction/perforation, differentiation, lymph node num-
ber (set at 12), and ECOG performance status, and if to 
receive chemotherapy within 8 weeks. The Kaplan–Meier 
technique (primary analysis) and compared survival with 
a stratified two-sided log-rank test were used to determine 
statistical significance. Cases were stratified by the number 
of FOLFOX cycles that patients received. In the order of 
titrating cycle numbers increasingly, survival analyses were 
done between all those cases above a certain cycle num-
ber (included) and all cases below that cycle number. If a 
significant difference was reached at certain cycle number, 
univariate Cox Regression was done for every demographic 
factor, including the number of cycles administered. Multi-
variate cox regression was further performed with all those 
factors resulting in p < 0.2 to determine if that cycle num-
ber was an independent prognostic factor. Statistical analy-
ses were performed using SPSS, version 22 (IBM Corp. 
Armonk, New York, USA). Significance was set at p < 0.05.
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